Generate Biomedicines, Inc. Common Stock GENB
i
Market dataready · fetched 2026-11-12T02:50:24.818Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T22:34:37.673227106Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-12T02:50:24.447369+00:00
Generate Biomedicines, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 15.89 | 105.9% | 20.3% | 9.65 | 490.9% | 42.3% |
| 25Δ | 15.24 | 103.1% | 16.0% | |||
| 30Δ | 14.81 | 102.4% | 13.6% | 12.56 | 91.7% | 9.3% |
| 35Δ | 14.52 | 103.1% | 12.3% | 12.82 | 91.0% | 8.5% |
| 40Δ | 14.22 | 103.7% | 11.1% | 13.07 | 90.4% | 7.7% |
| 45Δ | 13.93 | 104.3% | 9.8% | 13.33 | 89.7% | 6.9% |
| 50Δ | 13.63 | 104.9% | 8.6% | 13.58 | 89.0% | 6.0% |
| 55Δ | 13.34 | 105.5% | 7.3% | 13.84 | 88.4% | 5.2% |
| 60Δ | 13.04 | 106.2% | 6.0% | 14.09 | 87.7% | 4.4% |
| 65Δ | 12.75 | 106.8% | 4.8% | 14.35 | 87.1% | 3.6% |
| 70Δ | 12.38 | 113.1% | 3.7% | 14.60 | 86.4% | 2.8% |
| 75Δ | 11.56 | 150.9% | 3.6% | 14.85 | 85.7% | 2.0% |
| 80Δ | 10.75 | 188.8% | 3.5% | |||
20Δ
- Pseudo strike
- 15.89
- IV
- 105.9%
- B/E move
- 20.3%
- Pseudo strike
- 9.65
- IV
- 490.9%
- B/E move
- 42.3%
25Δ
- Pseudo strike
- 15.24
- IV
- 103.1%
- B/E move
- 16.0%
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 14.81
- IV
- 102.4%
- B/E move
- 13.6%
- Pseudo strike
- 12.56
- IV
- 91.7%
- B/E move
- 9.3%
35Δ
- Pseudo strike
- 14.52
- IV
- 103.1%
- B/E move
- 12.3%
- Pseudo strike
- 12.82
- IV
- 91.0%
- B/E move
- 8.5%
40Δ
- Pseudo strike
- 14.22
- IV
- 103.7%
- B/E move
- 11.1%
- Pseudo strike
- 13.07
- IV
- 90.4%
- B/E move
- 7.7%
45Δ
- Pseudo strike
- 13.93
- IV
- 104.3%
- B/E move
- 9.8%
- Pseudo strike
- 13.33
- IV
- 89.7%
- B/E move
- 6.9%
50Δ
- Pseudo strike
- 13.63
- IV
- 104.9%
- B/E move
- 8.6%
- Pseudo strike
- 13.58
- IV
- 89.0%
- B/E move
- 6.0%
55Δ
- Pseudo strike
- 13.34
- IV
- 105.5%
- B/E move
- 7.3%
- Pseudo strike
- 13.84
- IV
- 88.4%
- B/E move
- 5.2%
60Δ
- Pseudo strike
- 13.04
- IV
- 106.2%
- B/E move
- 6.0%
- Pseudo strike
- 14.09
- IV
- 87.7%
- B/E move
- 4.4%
65Δ
- Pseudo strike
- 12.75
- IV
- 106.8%
- B/E move
- 4.8%
- Pseudo strike
- 14.35
- IV
- 87.1%
- B/E move
- 3.6%
70Δ
- Pseudo strike
- 12.38
- IV
- 113.1%
- B/E move
- 3.7%
- Pseudo strike
- 14.60
- IV
- 86.4%
- B/E move
- 2.8%
75Δ
- Pseudo strike
- 11.56
- IV
- 150.9%
- B/E move
- 3.6%
- Pseudo strike
- 14.85
- IV
- 85.7%
- B/E move
- 2.0%
80Δ
- Pseudo strike
- 10.75
- IV
- 188.8%
- B/E move
- 3.5%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 77.99% | |
| 77.67% | |
| 73.39% | |
| 84.07% | |
| 75.75% | |
| 95.46% | |
| 71.15% | |
| 93.38% | |
| 79.99% | |
| 87.32% |
Biotechnology
GERN
Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The…
More →GHRS
GH Research PLC is a pioneering clinical-stage biopharmaceutical company focused on developing psilocybin-based therapies for psychiatric and neurodegenerative disorders. The…
More →GLUE
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new precision small molecule drugs that employ the body's natural mechanisms to selectively…
More →GMAB
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
More →GNLX
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive…
More →GPCR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet…
More →